Odelia Cooper1. 1. Pituitary Center, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Suite A6600, Los Angeles, CA, 90048, USA, coopero@cshs.org.
Abstract
PURPOSE: Silent corticotroph adenomas (SCAs) comprise 20% of all corticotroph adenomas and 3-19% of nonfunctioning adenomas (NFAs). As they do not manifest clinical or biochemical hypercortisolism, they are diagnosed after pathologic examination of resected tumor tissue demonstrates positive ACTH expression. While preoperative features are similar to those of NFAs, SCAs may have more cavernous sinus invasion. Further, patients with SCAs tend to have more frequent and earlier recurrences than those with NFAs, often necessitating multiple surgeries and other modalities of treatment. This article reviews the incidence, pathogenesis, and clinical behavior of SCAs. METHODS: A systematic literature review was performed using PubMed for information regarding SCAs. RESULTS: Up to date findings regarding epidemiology, pathogenesis, pathology, clinical presentation, postoperative course, and management of patients with SCAs are presented. CONCLUSION: This review highlights the necessity of rigorous monitoring for recurrences and hypopituitarism in patients with SCAs.
PURPOSE: Silent corticotroph adenomas (SCAs) comprise 20% of all corticotroph adenomas and 3-19% of nonfunctioning adenomas (NFAs). As they do not manifest clinical or biochemical hypercortisolism, they are diagnosed after pathologic examination of resected tumor tissue demonstrates positive ACTH expression. While preoperative features are similar to those of NFAs, SCAs may have more cavernous sinus invasion. Further, patients with SCAs tend to have more frequent and earlier recurrences than those with NFAs, often necessitating multiple surgeries and other modalities of treatment. This article reviews the incidence, pathogenesis, and clinical behavior of SCAs. METHODS: A systematic literature review was performed using PubMed for information regarding SCAs. RESULTS: Up to date findings regarding epidemiology, pathogenesis, pathology, clinical presentation, postoperative course, and management of patients with SCAs are presented. CONCLUSION: This review highlights the necessity of rigorous monitoring for recurrences and hypopituitarism in patients with SCAs.
Authors: Gabriel Zada; Whitney W Woodmansee; Shakti Ramkissoon; Jordan Amadio; Vania Nose; Edward R Laws Journal: J Neurosurg Date: 2010-09-24 Impact factor: 5.115
Authors: J Liu; C Lin; A Gleiberman; K A Ohgi; T Herman; H P Huang; M J Tsai; M G Rosenfeld Journal: Proc Natl Acad Sci U S A Date: 2001-07-10 Impact factor: 11.205
Authors: Olga Moshkin; Luis V Syro; Bernd W Scheithauer; Leon D Ortiz; Camilo E Fadul; Humberto Uribe; Ricardo Gonzalez; Michael Cusimano; Eva Horvath; Fabio Rotondo; Kalman Kovacs Journal: Hormones (Athens) Date: 2011 Apr-Jun Impact factor: 2.885
Authors: Marie S Thearle; Pamela U Freda; Jeffrey N Bruce; Steven R Isaacson; Yoomi Lee; Robert L Fine Journal: Pituitary Date: 2011-12 Impact factor: 4.107
Authors: Fabienne Langlois; Dawn Shao Ting Lim; Elena Varlamov; Chris G Yedinak; Justin S Cetas; Shirley McCartney; Aclan Dogan; Maria Fleseriu Journal: Endocrine Date: 2017-10-17 Impact factor: 3.633